ニュージャージー州プリンストン 2021年7月15日: Certara, a global leader in biosimulation, today announced the appointments of Nancy Killefer and Cynthia Collins to its board of directors, effective 2021年8月1日. The two additional appointments increase the company’s board of directors to eleven members.
“It’s truly a pleasure to welcome Nancy and Cynthia to the board of directors,” said Sheri McCoy, board chairman. “Their wealth of knowledge and extensive corporate board and leadership experience will be essential to us and no doubt strengthen our guidance of Certara.”
Ms. Killefer brings more than three decades of executive experience across the pharmaceutical, healthcare and technology sectors, most recently serving as director at McKinsey & Company until her retirement in 2013. She has also served in the public sector, specifically the United States Department of the Treasury as the assistant secretary for Management, chief financial officer and chief operating officer. Ms. Killefer is currently a member of the boards of Cardinal Health, Inc., Natura & Company, and Facebook, Inc.
Ms. Collins is a biotechnology industry veteran with more than 40 years of experience in gene and cell medicines and growing biotech companies. Most recently, she was the Chief Executive Officer of Editas Medicine, a gene editing biotechnology company, which experienced significant growth under her leadership, including dosing the first patient in the world with an in vivo gene edited therapy. Before Editas, Ms. Collins was CEO at several life sciences companies, including Human Longevity, GenVec and Sequoia Pharmaceuticals. Ms. Collins is currently a member of the board of DermTech, Inc.
“By providing model-informed insights into the safety and efficacy of novel drugs, Certara’s biosimulation software transforms how medicines are made across therapeutic areas,” said Ms. Killefer. “I look forward to helping the company accelerate drug discovery and development for the benefit of all patients.”
“Certara’s track record of scientific innovation and thought leadership is inspiring,” said Ms. Collins. “I am excited to bring my experience in scaling biotechnology companies to the Certara board and help steward the company towards continued success.”
Certara（サターラ）について
サターラは、バイオシミュレーションソフトウェアと技術を用いて、従来の創薬・開発を変革し、医薬品をよりスピーディーに患者さんに届けることをミッションとしています。バイオ医薬品企業1,650社以上、主要学術機関、主要な規制当局がサターラのソフトウェアやコンサルティングサービスを利用しております。弊社のお客様は61か国以上に広がっております。
投資家の皆様：
David Deuchler
Gilmartin Group
ir@certara.com
報道機関の皆様：
赤津 笑美
emi.akatsu@certara.com
ariane.lovell@finnpartners.com
